トゥーレット症候群 ： パイプライン分析

トゥーレット症候群(TS)とは神経障害の一種で、一定の非随意的な行動・発声を繰り返す（チックと呼ばれます）いう特徴があります。主な徴候として、瞬きなどの目のすばやい動きや、顔をゆがめる、肩をゆする、頭・肩の痙攣などが挙げられます。他にも、鼻に触る、ものの匂いを嗅ぐ、腕・脚をばたつかせる（フラッピング）といった症状が見られます。疾病素質には年齢などがあり、また男性の場合は発症の可能性が女性の3～4倍もあります。主な治療法には、抗うつ剤や興奮薬、行動療法などがあります。

当レポートでは、世界各国でのトゥーレット症候群治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

• 分析範囲

トゥーレット症候群の概要

治療薬の開発

• トゥーレット症候群向けパイプライン製品：概要
• トゥーレット症候群向けパイプライン製品：比較分析

各企業で開発中のトゥーレット症候群治療薬

パイプライン製品の概略

• 治験段階の製品
• 不明確な段階にある製品

トゥーレット症候群治療薬：開発中の製品の一覧（企業別）

トゥーレット症候群治療薬の開発に従事している企業

• AstraZeneca PLC
• Catalyst Pharmaceutical Partners, Inc.
• Edison Pharmaceuticals, Inc.
• Neurocrine Biosciences, Inc.
• Psyadon Pharmaceuticals, Inc.
• Reviva Pharmaceuticals Inc.
• Synchroneuron Inc.
• Teva Pharmaceutical Industries Limited

トゥーレット症候群：治療薬の評価

• 単剤治療薬の場合
• 標的別
• 作用機序別
• 投与方法別
• 分子の種類別

薬剤のプロファイル

• acamprosate calcium SR
  • 製品概要
  • 機能メカニズム
  • 研究開発(R&D)の進展状況
• AZD-5213
• CPP-115
• dutetrabenazine ER
• ecopipam hydrochloride
• RP-5063
• valbenazine
• vatiquinone
• vigabatrin

トゥーレット症候群治療薬：パイプライン製品の最新動向

トゥーレット症候群治療薬：開発が休止状態の製品

トゥーレット症候群治療薬：開発が中止された製品

トゥーレット症候群関連製品の開発のマイルストーン

• 注目すべき最新動向・プレスリリース

付録

図表一覧

List of Tables

List of Tables

• Number of Products under Development for Tourette Syndrome, H2 2020
• Number of Products under Development by Companies, H2 2020
• Number of Products under Development by Universities/Institutes, H2 2020
• Products under Development by Companies, H2 2020
• Products under Development by Universities/Institutes, H2 2020
• Number of Products by Stage and Target, H2 2020
• Number of Products by Stage and Mechanism of Action, H2 2020
• Number of Products by Stage and Route of Administration, H2 2020
• Number of Products by Stage and Molecule Type, H2 2020
• Tourette Syndrome - Pipeline by Adeptio Pharmaceuticals Ltd, H2 2020
• Tourette Syndrome - Pipeline by Asarina Pharma AB, H2 2020
• Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H2 2020
• Tourette Syndrome - Pipeline by Emalex Biosciences Inc, H2 2020
• Tourette Syndrome - Pipeline by Evero Health Ltd, H2 2020
• Tourette Syndrome - Pipeline by H. Lundbeck AS, H2 2020
• Tourette Syndrome - Pipeline by SOM Biotech SL, H2 2020
• Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2020
• Tourette Syndrome - Dormant Projects, H2 2020
• Tourette Syndrome - Discontinued Products, H2 2020

List of Figures

List of Figures

• Number of Products under Development for Tourette Syndrome, H2 2020
• Number of Products under Development by Companies, H2 2020
• Number of Products by Top 10 Targets, H2 2020
• Number of Products by Stage and Top 10 Targets, H2 2020
• Number of Products by Top 10 Mechanism of Actions, H2 2020
• Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
• Number of Products by Routes of Administration, H2 2020
• Number of Products by Stage and Routes of Administration, H2 2020
• Number of Products by Stage and Molecule Types, H2 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Pipeline Review, H2 2020, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to Buy:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

• Introduction
• Global Markets Direct Report Coverage
• Tourette Syndrome - Overview
• Tourette Syndrome - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Tourette Syndrome - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Tourette Syndrome - Companies Involved in Therapeutics Development
• Adeptio Pharmaceuticals Ltd
• Asarina Pharma AB
• Catalyst Pharmaceuticals Inc
• Emalex Biosciences Inc
• Evero Health Ltd
• H. Lundbeck AS
• SOM Biotech SL
• Teva Pharmaceutical Industries Ltd
• Tourette Syndrome - Drug Profiles
• alpha-dihydrotetrabenazine - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• bevantolol - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• CPP-115 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• deutetrabenazine - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Tourette Syndrome - Dormant Projects
• Tourette Syndrome - Discontinued Products
• Tourette Syndrome - Product Development Milestones
• Featured News & Press Releases
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer